No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 化妝品應用與管理系(所) > 期刊論文 > Item 310902800/34693

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34693

標題:	No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
作者:	Kang, Nai-Wen Kuo, Yu-Hsuan Wu, Hung-Chang Ho, Chung-Han Chen, Yi-Chen Yang, Ching-Chieh
貢獻者:	Chi Mei Hospital Department of Cosmetic Science, Chia Nan University of Pharmacy & Science Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy & Science Chi Mei Hospital Southern Taiwan University of Science & Technology Department of Pharmacy, Chia Nan University of Pharmacy & Science
關鍵字:	concurrent chemoradiotherapy mucoepidermoid carcinoma neck-cancer head radiotherapy management cisplatin outcomes tumors
日期:	2022
上傳時間:	2023-12-11 14:05:28 (UTC+8)
出版者:	NATURE PORTFOLIO
摘要:	This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009-2017) with advanced (T3-4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan-Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p=0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72-1.23) and DSS (aHR 0.96; 95% CI 0.72-1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection.
關聯:	SCIENTIFIC REPORTS, v.12, Article number: 20862
显示于类别:	[化妝品應用與管理系(所)] 期刊論文 [醫務管理系(所)] 期刊論文 [藥學系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	152	检视/开启
s41598-022-25468-9.pdf		1255Kb	Adobe PDF	52	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....